Skip to main content
Caplight Logo









Enterobiome Inc.

Enterobiome Inc.

Private
Goyang-siHealthcare & Life Scienceshttps://enterobiome.com/

Last Round

VC Round

Sep 27, 2024

Est. Valuation

$46.67M

Total Funding Raised

$14.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Enterobiome Inc. is a biotechnology company that develops microbiome-based pharmaceutical products and health-functional foods for the treatment of immune diseases, metabolic disorders, and other conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Non-AI

Keywords

microbiome therapeuticspharmabioticsmicrobiome drugsgut microbiomeanaerobic bacterianext-gen probioticsdrug discoveryAkkermansia muciniphilahealth-functional foodslive biotherapeutic productsLBPsgut healthbiotech startupclinical trialssupplements

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Enterobiome Inc. Comparables

Compare Enterobiome Inc. with similar companies based on industry and business-model similarity.

Enterobiome Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ImmunoBiome Inc.
88%
AtoGen Co., Ltd.
83%
Nodcure Inc.
82%

Enterobiome Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundSep 27, 2024
Series BJan 1, 2022
Series AJan 12, 2021
SeedJun 1, 2019

Key People

Founding team and executive leadership

Seo Jay

Chief Executive Officer

Executive Team

서재구

CEO

Executive Team

Enterobiome Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 34% MoM, reaching 3.3K.

  • Mar 3, 2026

    Monthly visitors increased 489% MoM, reaching 2.5K.

Enterobiome Inc. Filings

Explore SEC and related filing metadata, where available.

Enterobiome Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Enterobiome Inc.'s valuation, stock price, and market status.

Is Enterobiome Inc. a public or private company?

Enterobiome Inc. is a private company.

What is the current stock price of Enterobiome Inc.?

Enterobiome Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Enterobiome Inc. worth (valuation)?

Enterobiome Inc.'s valuation is estimated at $46.7M based on funding round data.

Can I buy Enterobiome Inc. stock?

Enterobiome Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Enterobiome Inc.'s last funding round?

Enterobiome Inc.'s most recent funding round was VC Round on January 1, 2022.

Who are the main investors in Enterobiome Inc.?

Key investors in Enterobiome Inc. include Magna Investment, Metistone Equity Partners.

Will Enterobiome Inc. IPO soon?

No public IPO plans have been announced for Enterobiome Inc..

How can I track Enterobiome Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Enterobiome Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersGoyang-si
Employee Range13
Year Founded2018
Last FundingSep 27, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?